WO2020151749A1 - 作为TGF-βR1激酶抑制剂的5-(4-吡啶氧基)吡唑类化合物 - Google Patents
作为TGF-βR1激酶抑制剂的5-(4-吡啶氧基)吡唑类化合物 Download PDFInfo
- Publication number
- WO2020151749A1 WO2020151749A1 PCT/CN2020/073832 CN2020073832W WO2020151749A1 WO 2020151749 A1 WO2020151749 A1 WO 2020151749A1 CN 2020073832 W CN2020073832 W CN 2020073832W WO 2020151749 A1 WO2020151749 A1 WO 2020151749A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- equivalent
- pharmaceutically acceptable
- isomer
- acceptable salt
- Prior art date
Links
- 0 *[n]1nc(CCC2)c2c1I Chemical compound *[n]1nc(CCC2)c2c1I 0.000 description 2
- KSTAACVNVDTPCC-UHFFFAOYSA-N CC(C)(c1cc(N)ccn1)O Chemical compound CC(C)(c1cc(N)ccn1)O KSTAACVNVDTPCC-UHFFFAOYSA-N 0.000 description 1
- RIIYENYPVGTKJJ-UHFFFAOYSA-N CC(C)(c1nccc(Nc2cc(Oc3cc(C)n[n]3-c3cccc(C)n3)ccn2)c1)O Chemical compound CC(C)(c1nccc(Nc2cc(Oc3cc(C)n[n]3-c3cccc(C)n3)ccn2)c1)O RIIYENYPVGTKJJ-UHFFFAOYSA-N 0.000 description 1
- HSYZCEHTRWCKAM-GSVOUGTGSA-N C[C@H](C1)C1(F)F Chemical compound C[C@H](C1)C1(F)F HSYZCEHTRWCKAM-GSVOUGTGSA-N 0.000 description 1
- RSDRDHPLXWMTRJ-UHFFFAOYSA-N C[n]1ncc(I)c1 Chemical compound C[n]1ncc(I)c1 RSDRDHPLXWMTRJ-UHFFFAOYSA-N 0.000 description 1
- ZEAMVRTVGSSARA-UHFFFAOYSA-N Cc(cc1Oc2ccnc(Cl)c2)n[n]1-c1cccc(C)n1 Chemical compound Cc(cc1Oc2ccnc(Cl)c2)n[n]1-c1cccc(C)n1 ZEAMVRTVGSSARA-UHFFFAOYSA-N 0.000 description 1
- RLSSMJSEOOYNOY-UHFFFAOYSA-N Cc1cc(O)ccc1 Chemical compound Cc1cc(O)ccc1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 1
- LLNQWPTUJJYTTE-UHFFFAOYSA-N Ic1c[nH]nc1 Chemical compound Ic1c[nH]nc1 LLNQWPTUJJYTTE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Definitions
- Transforming growth factor- ⁇ (Transforming growth factor- ⁇ , TGF- ⁇ ) is a multifunctional growth factor superfamily with a wide range of biological activities. It participates in early embryonic development, cartilage and bone formation, synthesis of outer matrix, inflammation, Interstitial fibrosis, regulation of immune and endocrine functions, formation and development of tumors.
- TGF- ⁇ signals can be directly transduced from the cell membrane such as in the nucleus.
- the TGF- ⁇ /Smads signaling pathway plays an important role in the occurrence and development of tumors. .
- activated TGF- ⁇ first binds to TGF- ⁇ R2 on the cell membrane surface to form a heterodimeric complex, and TGF- ⁇ R1 recognizes and binds to the binary complex.
- TGF- ⁇ is obviously related to immune escape and has a greater impact on the anti-tumor immune response mediated by CD8+ T cells.
- patients with high TGF- ⁇ gene expression responded to PD-L1 monoclonal antibody and had a low simulated survival rate.
- the basic research of TGF- ⁇ monoclonal antibody also proved that when it is used in conjunction with PD-L1 monoclonal antibody, more CD8+ T cells infiltrate and play a role, revealing the blocking effect of TGF- ⁇ on immune activation and its mechanism. Due to the immunomodulatory effect of TGF- ⁇ , small molecule TGF- ⁇ R1 inhibitors alone or in combination with PD-(L)1 monoclonal antibody have great application prospects in the treatment of various solid tumors.
- R 1 and R 2 are connected with the carbon atoms to which they are connected, so that Selected from R 3 is C 1-6 alkyl, 5-6 membered heteroaryl, phenyl or 5-6 membered heterocycloalkyl, wherein said C 1-6 alkyl, 5-6 membered heteroaryl, phenyl And 5-6 membered heterocycloalkyl are optionally substituted with 1, 2 or 3 R c ;
- R a, R b, R e and R f are each independently H, -CH 3, -CH 2 CH 3, -CH 2 CH 2 CH 3 or -CH (CH 3) 2;
- the 5-6 membered heteroaryl group and the 5-6 membered heterocycloalkyl group respectively contain 1, 2, 3 or 4 heteroatoms independently selected from N, -O- and -S-.
- R 1 and R 2 are each independently H, F, Cl, Br, -CN, -OCH 3 , -OCF 3 , -OCH 2 CH 3 , -CH 3 , -CF 3 , -CH 2 CH 3 , -CH(CH 3 ) 2 , -CH 2 CH 2 Cl, Other variables are as defined in the present invention.
- R 1 , R 3 and R 4 are as defined in the present invention.
- each R c is independently H, F, Cl, Br, I, -CN, -OH, -OCH 3 , -CH 3 or -CH 2 CH 3 , and other variables are as in the present invention Defined.
- the above-mentioned compounds have structures represented by formulas (I-A1) to (I-A3):
- R c and R 4 are as defined in the present invention.
- each of the foregoing Rds is independently H, -CN, Other variables are as defined in the present invention.
- R 4 is R d and other variables are as defined in the present invention.
- the pharmaceutically acceptable salt of the present invention can be synthesized from the parent compound containing an acid radical or a base by conventional chemical methods. Generally, such salts are prepared by reacting these compounds in free acid or base form with a stoichiometric amount of appropriate base or acid in water or an organic solvent or a mixture of both.
- enantiomer or “optical isomer” refers to stereoisomers that are mirror images of each other.
- the term “isomer excess” or “enantiomeric excess” refers to the difference between the relative percentages of two isomers or two enantiomers. For example, if the content of one isomer or enantiomer is 90% and the content of the other isomer or enantiomer is 10%, the isomer or enantiomer excess (ee value) is 80% .
- the term "effective amount” or “therapeutically effective amount” refers to a sufficient amount of a drug or agent that is non-toxic but can achieve the desired effect.
- the "effective amount” of one active substance in the composition refers to the amount required to achieve the desired effect when combined with another active substance in the composition.
- the determination of the effective amount varies from person to person, depending on the age and general condition of the recipient, and also on the specific active substance. The appropriate effective amount in a case can be determined by those skilled in the art according to routine experiments.
- the "5-6 membered ring” includes, for example, phenyl, pyridyl, piperidinyl and the like; on the other hand, the term “5-6 membered heterocycloalkyl” includes piperidinyl and the like, but does not include phenyl.
- the term “ring” also includes a ring system containing at least one ring, where each "ring" independently meets the above definition.
- CDCl 3 stands for deuterated chloroform
- DMSO stands for dimethyl sulfoxide
- Boc stands for tert-butoxycarbonyl.
- Step B Compound 5-1 (1 g, 5.29 mmol, 1 equivalent) and compound 1-4 (834.20 mg, 6.34 mmol, 1.2 equivalent) were dissolved in N,N-dimethylformamide (20 mL) Add potassium carbonate (2.19 g, 15.86 mmol, 3 equivalents), and react at 120 degrees Celsius for 8 hours. Cool to 25 degrees Celsius, dilute with water (50 mL), extract with ethyl acetate (30 mL ⁇ 3), combine the organic phases, wash with saturated brine (50 mL), dry with anhydrous sodium sulfate, filter, concentrate, and purify by column chromatography Compound 5-2 is obtained. MS(ESI) m/z: 301.1 [M+H + ].
- Step C Compound 5-2 (200 mg, 665.02 micromole, 1 equivalent), compound 3-1 (154.81 mg, 997.53 micromole, 1.5 equivalent), tris(dibenzylideneacetone) dipalladium (60.90 mg, 66.50 micromole, 0.1 equivalent), 4,5-bis(diphenylphosphine)-9,9-dimethylxanthene (76.96 mg, 133.00 micromole, 0.2 equivalent) and cesium carbonate (650.03 mg, 2.00 milli Mol, 3 equivalents) were sequentially added to dioxane (30 ml), replaced with nitrogen 3 times, and heated to 100 degrees Celsius and stirred for 12 hours.
- Step B The compound 5-2 (300 mg, 997.53 micromole, 1 equivalent), 11-2 (170.30 mg, 1.10 mmol, 1.1 equivalent), 4,5-bis(diphenylphosphine)-9,9 -Dimethylxanthene (115.44 mg, 199.51 micromole, 0.2 equivalent), cesium carbonate (975.04 mg, 2.99 mmol, 3 equivalent) and tris(dibenzylideneacetone) dipalladium (91.35 mg, 99.75 micromole) , 0.1 equivalent) was dissolved in 1,4-dioxane (10 ml). React at 100 degrees Celsius for 5 hours under a nitrogen atmosphere.
- Step A A solution of compound 12-1 (10 g, 69.65 mmol, 8.26 ml, 1 equivalent) in hydrazine hydrate (35.58 g, 696.52 mmol, 34.54 ml, 10 equivalent) was reacted at 120 degrees Celsius for 12 hours and concentrated to obtain Compound 12-2.
- Step B Dissolve compound 14-2 (8 g, 37.34 mmol, 1 equivalent) in a mixed solvent of acetic acid (50 mL) and water (50 mL), stir at 25 degrees Celsius for 1 hour, and add cyanoborohydride in batches Sodium (2.58 g, 41.07 mmol, 1.1 equivalent), react at 20 degrees Celsius for 2 hours. Adjust the pH to 7 with 1 mole per liter of sodium hydroxide aqueous solution, extract with dichloromethane (100 ml ⁇ 3), wash with saturated sodium bicarbonate aqueous solution (100 ml ⁇ 2), dry with anhydrous sodium sulfate, filter, and concentrate to obtain compound 14 -3.
- Step E Compound 14-5 (1.1 g, 6.04 mmol, 1 equivalent) and compound 1-4 (873.44 mg, 6.64 mmol, 1.1 equivalent) were dissolved in N,N-dimethylformamide (20 mL) Add potassium carbonate (2.5 g, 18.11 mmol, 3 equivalents) and react at 90 degrees Celsius for 12 hours. Dilute with water (50 mL) and extract with ethyl acetate (100 mL ⁇ 3). The organic phases were combined, washed with saturated brine (100 ml ⁇ 3), dried with anhydrous sodium sulfate, filtered, concentrated, and purified by column separation to obtain compound 14-6. MS(ESI) m/z: 294.1 [M+H + ].
- Step B Compound 16-1 (1.13 g, 5.43 mmol, 1 equivalent) and compound 1-4 (785.08 mg, 5.97 mmol, 1.1 equivalent) were dissolved in N,N-dimethylformamide (10 mL) Add potassium carbonate (2.25 g, 16.28 mmol, 3 equivalents) and react at 90 degrees Celsius for 8 hours. Cool, dilute with water (30 mL), and extract with ethyl acetate (30 mL ⁇ 3). The organic phases were combined, washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column separation to obtain compound 16-2. MS(ESI) m/z: 320.0 [M+H + ].
- Step D Dissolve compound 16-3 (177 mg, 440.89 ⁇ mol, 1 equivalent) in ethanol (5 mL), add aqueous sodium hydroxide solution (1 mol per liter, 440.89 ⁇ l, 1 equivalent), dimethyl Sulfoxide (68.90 mg, 881.78 ⁇ mol, 68.90 ⁇ mol, 2 equivalents) and hydrogen peroxide (99.98 mg, 881.78 ⁇ mol, 84.73 ⁇ l, purity 30%, 2 equivalents) were reacted at 25 degrees Celsius for 4 hours.
- aqueous sodium hydroxide solution (1 mol per liter, 440.89 ⁇ l, 1 equivalent
- dimethyl Sulfoxide 68.90 mg, 881.78 ⁇ mol, 68.90 ⁇ mol, 2 equivalents
- hydrogen peroxide 99.98 mg, 881.78 ⁇ mol, 84.73 ⁇ l, purity 30%, 2 equivalents
- Step A 14-4 (3 g, 15.87 mmol, 1 equivalent) and 18-1 (2.60 g, 16.66 mmol, 89.55 ⁇ l, 1.05 equivalent) were dissolved in acetic acid (20 mL) at 80 degrees Celsius under nitrogen atmosphere React for 12 hours. Cool, concentrate, dilute with water (100 ml), adjust the pH of the solution to 7 with saturated aqueous sodium bicarbonate solution. Dichloromethane (100 mL ⁇ 2) was added for extraction. The organic phases were combined, washed with water (100 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column separation to obtain compound 18-2. MS(ESI) m/z: 209.0 [M+H + ].
- Step B Compound 18-2 (1 g, 4.8 mmol, 1 equivalent) and 1-4 (694.76 mg, 5.28 mmol, 1.1 equivalent) were dissolved in N,N-dimethylformamide (10 mL) , Potassium carbonate (2.65 g, 19.21 mmol, 4 equivalents) was added and reacted at 100 degrees Celsius for 4 hours. Dilute with water (100 mL) and extract with ethyl acetate (90 mL ⁇ 2). The organic phases were combined, washed with saturated brine (90 mL), dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column separation to obtain compound 18-3. MS(ESI) m/z: 320.1 [M+H + ].
- Step C Compound 18-3 (300 mg, 938.13 ⁇ mol, 1 equivalent), 1-6 (121.91 mg, 1.03 mmol, 96.31 ⁇ l, 1.1 equivalent), 4,5-bis(diphenylphosphine) -9,9-Dimethylxanthene (54.28 mg, 93.81 ⁇ mol, 0.1 equivalent), cesium carbonate (916.98 mg, 2.81 mmol, 3 equivalents) and palladium acetate (21.06 mg, 93.81 ⁇ mol, 0.1 equivalents) Dissolve in dioxane (4 ml) and react at 100 degrees Celsius for 3 hours under a nitrogen atmosphere.
- TGF ⁇ was purchased from PeproTech.
- the compound to be tested was diluted 5 times with a discharge gun to the 8th concentration, that is, diluted from 1 millimolar per liter to 12.8 nanomolar per liter, the final concentration of dimethyl sulfoxide was 100%, and a double-multi-hole experiment was set up.
- Add 2 microliters of inhibitors of each concentration gradient 18 microliters of TGF ⁇ (20 ng per milliliter), 180 microliters of cell suspension (140,000 cells per milliliter), and the final concentration gradient of the compound is 10 microliters.
- the mole per liter is diluted to 0.13 nanomole per liter.
- the cell plate was placed at 37 degrees Celsius in a 5% CO 2 incubator and continued for 24 hours.
- the compound of the present invention has excellent pSmad inhibitory activity. It is proved that the compound of the present invention can inhibit the TGF- ⁇ /SMAD signal pathway.
- the purpose of this experiment is to evaluate the pharmacokinetic behavior of the compound after single intravenous injection and intragastric administration, and to investigate the bioavailability after intragastric administration.
- the compound of the present invention Compared with compound A reported in the literature, the compound of the present invention has longer half-life, wider tissue distribution, and significantly improved bioavailability. It has significantly better pharmacokinetic properties than compound A.
- T max time to peak concentration
- F bioavailability
Abstract
Description
化合物 | pSmad抑制IC 50(纳摩尔每升) |
化合物1 | 65.45 |
化合物2 | 246.8 |
化合物3 | 54.27 |
化合物4 | 53.83 |
化合物5 | 440.8 |
化合物6 | 79.15 |
化合物7 | 354.1 |
化合物8 | 683.9 |
化合物9 | 267.7 |
化合物10 | 354.7 |
化合物11 | 191 |
化合物12 | 432.3 |
化合物13 | 59.58 |
化合物14 | 335.5 |
化合物15 | 415.9 |
化合物16 | 165.7 |
化合物17 | 620.9 |
化合物18的三氟乙酸盐 | 282.9 |
化合物19 | 587 |
Claims (22)
- 式(I)所示化合物、其药学上可接受的盐或其异构体,其中,R 1和R 2各自独立地为H、F、Cl、Br、-CN、 C 1-3烷氧基、C 1-3烷基或C 3-6环烷基,其中所述C 1-3烷氧基、C 1-3烷基和C 3-6环烷基任选被1、2或3个独立选自F或Cl的取代基所取代;R 3为C 1-6烷基、5-6元杂芳基、苯基或5-6元杂环烷基,其中所述C 1-6烷基、5-6元杂芳基、苯基和5-6元杂环烷基任选被1、2或3个R c所取代;各R c独立地为H、F、Cl、Br、I、-CN、-OH、C 1-3烷氧基或C 1-3烷基;R 4为5-6元杂芳基或苯基,其中所述5-6元杂芳基和苯基任选被1、2或3个R d所取代;R a、R b、R e和R f各自独立地为H、-CH 3、-CH 2CH 3、-CH 2CH 2CH 3或-CH(CH 3) 2;所述5-6元杂芳基和5-6元杂环烷基分别包含1、2、3或4个独立选自N、-O-和-S-的杂原子。
- 根据权利要求1所述化合物、其药学上可接受的盐或其异构体,其中所述各R c独立地为H、F、Cl、Br、I、-CN、-OH、-OCH 3、-CH 3或-CH 2CH 3。
- 根据权利要求1~6任一项所述化合物、其药学上可接受的盐或其异构体,其中所述R 3为C 1-3烷基、吡啶基、苯基或四氢-2H-吡喃基,其中所述C 1-3烷基、吡啶基、苯基和四氢-2H-吡喃基任选被1、2或3个R c所取代。
- 根据权利要求1、4、5或10~13任一项所述化合物、其药学上可接受的盐或其异构体,其中所述R 4为吡咯基、吡唑基、吡啶基、吡嗪基、嘧啶基或苯基,其中所述吡咯基、吡唑基、吡啶基、吡嗪基、嘧啶基和苯基任选被1、2或3个R d所取代。
- 根据权利要求1~19任一项所述化合物、其药学上可接受的盐或其异构体在制备TGF-βR1抑制剂药物中的应用。
- 根据权利要求1~19任一项所述化合物、其药学上可接受的盐或其异构体在制备实体瘤药物中的应用。
- 一种含有治疗有效量的根据权利要求1~19任一项所述化合物、其药学上可接受的盐或其异构体,和药学上可接受的载体的药物组合物。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/425,426 US20220098171A1 (en) | 2019-01-24 | 2020-01-22 | 5-(4-PYRIDYLOXY)PYRAZOLE COMPOUNDS SERVING AS TGF-ßR1 KINASE INHIBITOR |
EP20744402.7A EP3922631A4 (en) | 2019-01-24 | 2020-01-22 | 5-(4-PYRIDYLOXY)PYRAZOLE COMPOUNDS AS A TGF-BETA R1 KINASE INHIBITOR |
JP2021543265A JP7331116B2 (ja) | 2019-01-24 | 2020-01-22 | TGF-βR1キナーゼ阻害剤としての5-(4-ピリジルオキシ)ピラゾール類化合物 |
KR1020217026698A KR20210118891A (ko) | 2019-01-24 | 2020-01-22 | TGF-β R1 키나아제 억제제로서의 5-(4-피리딜옥시)피라졸 화합물 |
CN202080009676.0A CN113316575B (zh) | 2019-01-24 | 2020-01-22 | 作为TGF-βR1激酶抑制剂的5-(4-吡啶氧基)吡唑类化合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910069936 | 2019-01-24 | ||
CN201910069936.2 | 2019-01-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020151749A1 true WO2020151749A1 (zh) | 2020-07-30 |
Family
ID=71735851
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/073832 WO2020151749A1 (zh) | 2019-01-24 | 2020-01-22 | 作为TGF-βR1激酶抑制剂的5-(4-吡啶氧基)吡唑类化合物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220098171A1 (zh) |
EP (1) | EP3922631A4 (zh) |
JP (1) | JP7331116B2 (zh) |
KR (1) | KR20210118891A (zh) |
CN (1) | CN113316575B (zh) |
WO (1) | WO2020151749A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022017208A1 (zh) * | 2020-07-23 | 2022-01-27 | 江苏奥赛康药业有限公司 | 作为TGF-βR1抑制剂的吡啶氧基连吡唑类化合物的盐型、晶型以及其药物组合物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020258006A1 (en) * | 2019-06-25 | 2020-12-30 | Inventisbio Shanghai Ltd. | Heterocyclic compounds, preparation methods therefor, and methods of uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002094833A1 (en) | 2001-05-24 | 2002-11-28 | Eli Lilly And Company | Novel pyrrole derivatives as pharmaceutical agents |
TW201329067A (zh) * | 2011-12-08 | 2013-07-16 | Amgen Inc | 作為gka活化劑之脲化合物 |
WO2016057278A1 (en) | 2014-10-07 | 2016-04-14 | Eli Lilly And Company | Aminopyridyloxypyrazole compounds |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106470992B (zh) * | 2014-06-17 | 2018-11-06 | 正大天晴药业集团股份有限公司 | 作为pi3k抑制剂的吡啶并[1,2-a]嘧啶酮类似物 |
CA3050346C (en) * | 2017-01-22 | 2020-07-14 | Fujian Cosunter Pharmaceutical Co., Ltd. | Pyridine derivative as ask1 inhibitor and preparation method and use thereof |
WO2020258006A1 (en) | 2019-06-25 | 2020-12-30 | Inventisbio Shanghai Ltd. | Heterocyclic compounds, preparation methods therefor, and methods of uses thereof |
-
2020
- 2020-01-22 EP EP20744402.7A patent/EP3922631A4/en active Pending
- 2020-01-22 CN CN202080009676.0A patent/CN113316575B/zh active Active
- 2020-01-22 WO PCT/CN2020/073832 patent/WO2020151749A1/zh unknown
- 2020-01-22 US US17/425,426 patent/US20220098171A1/en active Pending
- 2020-01-22 KR KR1020217026698A patent/KR20210118891A/ko not_active Application Discontinuation
- 2020-01-22 JP JP2021543265A patent/JP7331116B2/ja active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002094833A1 (en) | 2001-05-24 | 2002-11-28 | Eli Lilly And Company | Novel pyrrole derivatives as pharmaceutical agents |
CN1951939A (zh) * | 2001-05-24 | 2007-04-25 | 伊莱利利公司 | 作为药物的新的吡唑衍生物 |
TW201329067A (zh) * | 2011-12-08 | 2013-07-16 | Amgen Inc | 作為gka活化劑之脲化合物 |
WO2016057278A1 (en) | 2014-10-07 | 2016-04-14 | Eli Lilly And Company | Aminopyridyloxypyrazole compounds |
CN106795139A (zh) * | 2014-10-07 | 2017-05-31 | 伊莱利利公司 | 氨基吡啶基氧基吡唑化合物 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022017208A1 (zh) * | 2020-07-23 | 2022-01-27 | 江苏奥赛康药业有限公司 | 作为TGF-βR1抑制剂的吡啶氧基连吡唑类化合物的盐型、晶型以及其药物组合物 |
Also Published As
Publication number | Publication date |
---|---|
US20220098171A1 (en) | 2022-03-31 |
JP2022518544A (ja) | 2022-03-15 |
KR20210118891A (ko) | 2021-10-01 |
EP3922631A1 (en) | 2021-12-15 |
CN113316575B (zh) | 2022-03-18 |
JP7331116B2 (ja) | 2023-08-22 |
EP3922631A4 (en) | 2022-10-26 |
CN113316575A (zh) | 2021-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115335372B (zh) | 八氢吡嗪并二氮杂萘啶二酮类化生物 | |
EP3470409B1 (en) | Benzotriazole-derived alpha and beta-unsaturated amide compound used as tgf-beta ri inhibitor | |
JP6948659B1 (ja) | ピリダジニルチアアゾールカルボキシアミド化合物 | |
WO2020259573A1 (zh) | 作为kras g12c突变蛋白抑制剂的七元杂环类衍生物 | |
TW202128662A (zh) | 一種蛋白降解劑化合物的製備方法和應用 | |
WO2020151749A1 (zh) | 作为TGF-βR1激酶抑制剂的5-(4-吡啶氧基)吡唑类化合物 | |
JP2022542162A (ja) | ヘテロ環式アミド化合物及びその製造方法並びに使用 | |
CN114746413A (zh) | 二氮杂吲哚类衍生物及其作为Chk1抑制剂的应用 | |
TWI807697B (zh) | 呋喃稠環取代的戊二醯亞胺類化合物 | |
WO2021058024A1 (zh) | Lsd1抑制剂 | |
CN112839946B (zh) | 作为TGF-βR1激酶抑制剂的双环吡唑类化合物 | |
CN114008046B (zh) | 作为cdk9抑制剂的氮杂吲哚连吡唑类化合物 | |
US20230095530A1 (en) | Compound used as ret kinase inhibitor and application thereof | |
CN116375707A (zh) | Menin抑制剂及其用途 | |
WO2021218912A1 (zh) | 含苯基并内磺酰胺的化合物 | |
WO2023016527A1 (zh) | 一类苯并噁嗪螺环类化合物及其制备方法 | |
WO2021004533A1 (zh) | 作为irak4和btk多靶点抑制剂的噁唑类化合物 | |
WO2020156568A1 (zh) | 作为pd-l1免疫调节剂的氟乙烯基苯甲酰胺基化合物 | |
WO2020156564A1 (zh) | 作为pd-l1免疫调节剂的乙烯基吡啶甲酰胺基化合物 | |
TWI795129B (zh) | 吡啶并嘧啶酮類化合物 | |
WO2020147774A1 (zh) | 喹唑啉衍生物在制备治疗鼻咽癌药物中的应用 | |
CN114787145B (zh) | 作为转化生长因子-β受体I/ALK5抑制剂的苯甲酰胺衍生物 | |
WO2022022646A1 (zh) | 含硒五元杂芳环化合物 | |
WO2022152316A1 (zh) | 联苯衍生物及其应用 | |
WO2021204252A1 (zh) | 作为乙肝表面抗原抑制剂的四环化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20744402 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021543265 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20217026698 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020744402 Country of ref document: EP Effective date: 20210824 |
|
ENP | Entry into the national phase |
Ref document number: 2020744402 Country of ref document: EP Effective date: 20210824 |